Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Epitope-optimized alpha-fetoprotein genetic vaccines prevent carcinogen-induced murine autochthonous hepatocellular carcinoma

12 Oct 2013

Abstract excerpt

UNLABELLED: Immunization with effective cancer vaccines can offer a much needed adjuvant therapy to fill the treatment gap after liver resection to prevent relapse of hepatocellular carcinoma (HCC). However, current HCC cancer vaccines are mostly based on native shared-self/tumor antigens that are only able to induce weak immune responses. In this study we investigated whether the HCC-associated self/tumor...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Hepatocellular Carcinoma Treatment and Prognosis
Share to Immunotherapy and Immune Responses

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 24122861
DOI: 10.1002/hep.26893

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Epitope-optimized alpha-fetoprotein genetic vaccines prevent carcinogen-induced murine autochthonous hepatocellular carcinomaPMID 24122861Read ↗

Selection of a Clinical Lead TCR Targeting Alpha-Fetoprotein-Positive Liver Cancer Based on a Balance of Risk and BenefitSemantic proximity Read ↗

Neoantigens as potential vaccines in hepatocellular carcinomaSemantic proximity Read ↗

Oncogenic viral antigens for engineered T cell immunotherapy: Challenges and opportunitiesSemantic proximity Read ↗

Neoantigen Specific T Cells Derived From T Cell-Derived Induced Pluripotent Stem Cells for the Treatment of Hepatocellular Carcinoma: Potential and Challenges.Semantic proximity Read ↗

Oncolytic adenovirus delivery of neoantigens sensitizes low-mutation tumors to anti-PD-1 therapy and prevents metastasis.Semantic proximity Read ↗

Non-canonical ORFs are an important source of tumor-specific antigens in a liver cancer meta-cohortSemantic proximity Read ↗

High-affinity neoantigens correlate with better prognosis and trigger potent antihepatocellular carcinoma (HCC) activity by activating CD39 + CD8 + T cellsSemantic proximity Read ↗

Use of Expression Profiles of HBV-DNA Integrated Into Genomes of Hepatocellular Carcinoma Cells to Select T Cells for ImmunotherapySemantic proximity Read ↗

Enhancement of tumor-associated antigen-specific T cell responses by radiofrequency ablation of hepatocellular carcinoma.Semantic proximity Read ↗

T cell responses to HLA-A*0201-restricted peptides derived from human alpha fetoprotein.Semantic proximity Read ↗

Cancer immunotherapy: exploiting neoepitopes.Semantic proximity Read ↗

Rethinking Antigen Source: Cancer Vaccines Based on Whole Tumor Cell/tissue Lysate or Whole Tumor CellSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.